Last updated: April 23, 2026
What suppliers provide ergotamine tartrate, and what categories do they fall into?
Ergotamine tartrate is an API that is sourced through (1) API manufacturers and (2) distributors/wholesalers that carry drug substances and/or intermediate-grade materials. Based on the established commercial supply pattern for ergot alkaloids (API and intermediate sourcing via specialty chemical and pharmaceutical ingredient channels), the supplier set typically includes:
- API manufacturers (ergot alkaloid / ergotamine base chain) supplying ergotamine tartrate or convertible ergotamine salt forms
- Specialty chemical and pharma ingredient distributors selling ergotamine tartrate to formulation and contract manufacturing organizations (CMOs)
Operational note for procurement: ergotamine tartrate supply is often routed through specialty channels because the supply chain is tightly tied to controlled-alkaloid handling, documentation, and batch traceability.
Who are the main supplier types to target for ergotamine tartrate procurement?
Below is the target supplier universe by procurement category, which is how buyers structure sourcing for this API.
1) API manufacturers
These suppliers typically provide:
- Full CoA per batch (identity, assay, impurities, moisture, residual solvents where applicable)
- DMF/ASMF support where available (or letter of suitability)
- Qualification packages for GMP manufacture and documentation
2) Specialty pharma ingredient distributors
These suppliers typically provide:
- API/chemical product catalog availability
- Batch-level documentation and logistics support
- Supply continuity via inventory, including multi-vendor sourcing
3) Contract manufacturers (when switching from tartrate to salt/form)
Some CMOs do not market “ergotamine tartrate” as a catalog API but can source it and/or support conversion into the required salt form and specification for a finished dosage form. This is relevant if the target specification is stricter than typical catalog grades.
What specifications should suppliers meet for ergotamine tartrate to be usable in pharmaceutical programs?
Procurement and quality teams typically require a minimum specification package aligned to pharma use.
Core documentation package
- CoA (assay, identity, impurities)
- GMP status (where applicable)
- Analytical method references (USP/EP/ChP methods or vendor method)
- Traceability (batch/lot control)
- Stability or referenced handling/storage guidance (for supply chain planning)
Typical quality checks buyers screen
- Identity by validated method (commonly HPLC/LC or spectroscopic confirmation)
- Assay within stated limits
- Impurity profile consistency batch-to-batch
- Water content (if specified)
- Residual solvents (if applicable)
How to short-list the best suppliers for ergotamine tartrate
Use a two-stage funnel that matches ergotamine tartrate supply realities (small number of reliable producers, heavy documentation requirements).
Stage 1: Commercial availability + documentation readiness
- Supplier provides CoA on request for recent lots
- Supplier states intended use (pharma grade vs. chemical grade)
Stage 2: Technical fit
- Supplier can meet your impurity/spec limits
- Supplier supports regulatory documentation needs (DMF/ASMF or a formal qualification packet)
Key supplier decision points by buyer type
For API procurement (CMO-to-manufacturing chain)
Prioritize suppliers that can provide:
- Batch-level CoAs
- Consistent impurity profiles
- GMP-aligned documentation
For formulation R&D
Prioritize suppliers that can provide:
- Consistent salt form (tartrate confirmation)
- Analytical method transparency (or reproducible test results)
- Fast lead times for trial batches
Key Takeaways
- Supplier sourcing for ergotamine tartrate typically clusters around API manufacturers and specialty pharma ingredient distributors, with tight documentation expectations due to the alkaloid nature of the material.
- Short-list suppliers by: (1) availability and CoA immediacy, then (2) impurity/spec consistency and documentation fit (GMP/DMF support where needed).
- The procurement path should be built around batch traceability, pharma-grade documentation, and validated analytical support rather than price alone.
FAQs
1) What supplier category is usually safest for pharmaceutical development?
An API manufacturer that can supply pharma-grade documentation and batch-level CoAs aligned to intended use.
2) Do distributors provide sufficient documentation for R&D?
Often yes for early-stage work, but the buyer should screen for batch CoA recency, impurity reporting, and intended-use statements.
3) What is the main risk when sourcing ergotamine tartrate?
Inconsistent salt form and impurity profiles, plus gaps in pharma-grade documentation and traceability.
4) Is GMP status always required to purchase ergotamine tartrate?
For routine commercial supply it is typically required; for early R&D it depends on your internal and customer requirements, but the best supplier still provides GMP-aligned documentation.
5) How do buyers qualify a new ergotamine tartrate supplier?
By confirming identity/assay, reviewing impurity limits, evaluating batch-to-batch consistency, and obtaining a complete qualification package (CoA plus regulatory/quality documents).
References
[1] USP (United States Pharmacopeia). “USP–NF Monographs.” https://www.uspnf.com/ (accessed 2026-04-23).
[2] European Pharmacopoeia (Ph. Eur.). “European Pharmacopoeia Online.” https://online6.edqm.eu/ (accessed 2026-04-23).
